Curanex Pharmaceuticals Inc (CURX) is a clinical-stage biotechnology company developing botanical drug candidates targeting inflammatory diseases. The company generates no product revenue and has not generated any revenue during the fiscal years ended December 31, 2025, or December 31, 2024, per its 10-K filed March 30, 2026. Revenue is anticipated only upon successful commercialization or through strategic licensing agreements. Curanex's lead candidate, Phyto-N, is being developed across multiple inflammatory indications, with an IND submission for ulcerative colitis planned for the fourth quarter of 2026. The company had 28,364,812 shares of common stock and 1,000,000 shares of Series A Preferred Stock outstanding as of the filing date. General and administrative expenses were $1,253,203 for FY2025, up from $290,386 in FY2024, driven primarily by post-IPO payroll costs and public company compliance expenses. Curanex completed its IPO through underwriter Dominari Securities, LLC, in August 2025 and is incorporated in Nevada.

Revenue model

No revenue generated in FY2025 or FY2024. Future revenue is contingent on commercialization of product candidates or licensing agreements with third parties. No commercial products are approved or on market as of the 10-K filing date of March 30, 2026.

Products and services

Phyto-N is the company's sole disclosed drug candidate, a botanical drug being developed for multiple inflammatory indications including ulcerative colitis (lead indication), atopic dermatitis, nonalcoholic fatty liver disease (prevention and treatment), diabetes, COVID-19 (prevention and treatment), gouty nephritis, and gouty arthritis. An IND for ulcerative colitis is planned for Q4 2026.

Customers and end markets

No commercial customers as of the 10-K filing date. Target end markets are patients with inflammatory diseases, specifically those with ulcerative colitis, atopic dermatitis, NAFLD, diabetes, COVID-19, and gout-related conditions. No revenues or customer contracts are disclosed.

Value-chain role

Pre-commercial drug developer. Curanex conducts preclinical and plans clinical-stage development of botanical drug candidates and intends to seek FDA regulatory approval. The company may also license indications to third parties at the Phase II stage.

Geographic exposure

Incorporated in Nevada. Plans to seek regulatory approval in the United States and foreign countries. No commercial operations or disclosed geographic revenue as of the 10-K filing date.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations